Transcription factors are DNA-binding proteins that regulate the expression of specific genes by controlling transcription initiation. Two families of transcription factors, NFκB and AP-1, play pivotal roles in controlling important cellular processes ranging from normal cell growth and differentiation to apoptosis and cancer. Identifying changes in the DNA-binding activity of these factors is essential to understanding the regulation of these processes. We have developed a high-throughput DNAbased ELISA capable of monitoring activated levels of NFκB (p50 and p65) and AP-1 (c-Jun and c-Fos). This chemiluminescent assay utilizes a 96-well plate format, eliminating the throughput challenges imposed by traditional gel shift assays and exceeding the sensitivity and dynamic range of standard colorimetric detection systems. The sensitivity of this assay enables distinction between subtle as well as dramatic differences in the DNA-binding activity of these factors that result from the treatment of cells with various inhibitors or activating agents. (Journal of Biomolecular Screening 2004:334-342) Key words: transcription factors, chemiluminescence, electrophoretic mobility shift assay (EMSA), nuclear factor kappa B (NFκB), activator protein-1 (AP-1), DNA-binding proteins, gel shift assay 334 www.sbsonline.org
INTRODUCTION
A S RESEARCHERS CONTINUE TO DISSECT THE COMPLEXITIES of gene expression, they are discovering how the expression of many genes is regulated at the level of transcription initiation. 1 Transcription factors, DNA-binding proteins that regulate gene expression at this level, are, therefore, becoming targets of intense research interest particularly in the area of drug discovery. Understanding their function is essential to understanding the transcription process and how it is regulated. Two transcription factors that are of common interest because of their implication in many normal cellular processes as well as disease states are nuclear factor kappa B (NFκB) and activator protein-1 (AP-1).
NFκB proteins are sequence-specific transcription factors involved in the activation of an exceptionally large number of genes implicated in immune function, inflammation, antiapoptotic responses, 2,3 cellular growth control, and cancer, as well as control of expression of certain viruses such as the human immunodeficiency virus (HIV). 4 The proteins encoded by these genes include cytokines, chemokines, cell adhesion molecules, growth factors, and immunoreceptors. 5 Consequently, NFκB has become one of the most intensively studied transcription factors of the last decade. The pivotal role played by NFκB is illustrated not only by the great diversity of genes that it regulates but also by the large variety of stimuli leading to its activation. 6 Due to this role in a wide variety of diseases, NFκB has become a major target for drug development. 7 NFκB typically exists as a homodimer of the p50 subunit or as a heterodimer of the p50 and p65 proteins. In unstimulated cells, these dimers exist in an inactive state in the cytoplasm complexed to inhibitory I kappa B (IκB) molecules. 8 Stimulation occurs when extracellular signals or cell-to-cell interactions are converted into intracellular activation signals through receptor molecules located in the cell membrane. 9 Upon stimulation, IκB is rapidly degraded, freeing NFκB dimers to translocate into the nucleus, bind to target DNA elements, 10 and activate the expression of their target genes. 8 Activating protein-1 (AP-1) is a dimeric complex composed of proteins encoded by the Jun and Fos gene families. 11 These basic region leucine-zipper (B-ZIP) transcription factors dimerize via their leucine-zipper domains, which, in turn, bring together their basic domains to bind DNA in a sequence-specific manner. 12 The AP-1 components c-Fos and c-Jun are nuclear transcription factors that have been implicated in the regulation of genes involved in immune responses, developmental processes, inflammation, and diseases such as cancer. [13] [14] [15] [16] [17] AP-1 is required for transformation by many oncogenes, which function upstream of it in the growth factor-ras signal transduction pathway. 18 AP-1 is known to play a role in cell proliferation, neuronal activation, and the apoptotic pathway triggered in response to stress, DNA damaging agents, or lack of survival signals. Moreover, such studies have identified some of the target genes that mediate the effects of AP-1 proteins on cell proliferation and death. 14 Activation of AP-1 may occur through a variety of stimuli including inflammatory cytokines, neurotransmitters, and growth factors, in addition to those eliciting proliferation, differentiation, and programmed cell death (apoptosis). 11 The activation process involves both an increase in de novo synthesis of AP-1 subunits and phosphorylation of existing Fos and Jun proteins. The ability to screen for c-Fos and c-Jun stimulation is, therefore, important to drug discovery as well as to gene regulation studies.
We have developed a high-throughput assay for the transcription factors NFκB and AP-1. Based on enhanced chemiluminescent luminol technology, 19 this assay rivals the sensitivity of traditional methods and facilitates the quick screening of small molecule libraries for potential drug development. The assay is simple, robust, and reproducible for the detection of NFκB p50, NFκB p65, c-Fos, and c-Jun in rat, mouse, and human cell lines. Binding and washing conditions are based on standard ELISA protocols, making this assay amenable to large high-throughput robotic applications. In this report, we illustrate the sensitivity and utility of this assay and demonstrate its value in screening both stimulators and inhibitors of these transcription factors.
MATERIALS AND METHODS

Materials
The penicillin/streptomycin and amphotericin B were purchased from Invitrogen (Carlsbad, CA), whereas all cell culture media and supplements were purchased from HyClone (Logan, UT). Halt™ protease inhibitors and extraction reagents other than RIPA buffer, as well as interleukin-1β, interleukin-2, interleukin-15, granulocyte macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor alpha (TNF-α) were purchased from Pierce Biotechnology (Rockford, IL). Curcumin, kamebakaurin, and nordihydroguaiaretic acid (NDGA) were obtained from Calbiochem (San Diego, CA). Ammonium pyrrolidinedithiocarbamate (PDTC), dimethyl sulfoxide (DMSO), ionomycin, phorbol 12-myristate 13-acetate (PMA), lipopolysaccharide (LPS), and sodium orthovanadate were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culturing
HeLa, NIH3T3, and rat C6 cells were grown in Dulbecco's Modified Eagle's medium supplemented with 10% fetal calf serum, 100 units/ml of penicillin/streptomycin, 0.25 µg/ml amphotericin B, 2 mM L-glutamine, and 1 mM sodium pyruvate.
Cell stimulation
Cells were grown to a confluency of 70% to 80%. HeLa and C6 cells were activated with 25 ng/ml TNF-α for 20 min or 55 ng/ml PMA/1 µM ionomycin for 3 h. For the stimulation of NFκB p65 and c-Fos in NIH3T3 cells, 55 ng/ml PMA/1 µM ionomycin, 10 ng/ml IL-1β, 5 nM IL-2, 20 nM IL-15, 100 ng/ml LPS, or 100 µg/ ml GM-CSF was added to the media and incubated for 60 min or 25 ng/ml TNF-α for 20 min. PMA and ionomycin were suspended in DMSO; all other inducers were suspended in water. DMSO controls demonstrate that PMA/ionomycin effects are not attributable to the vehicle used (data not shown).
Oligonucleotides
Wild-type (5′-CACAGTTGAGGGGACTTTCCCAGGC-3′) and mutant (5′-CACAGTTGAGGCCACTTTCCCAGGC-3′) NFκB sense and antisense consensus oligonucleotides, as well as wild-type (5′-ACACCGCTTGATGAGTCAGCCGGAA-3′) and mutant (5′-ACACCGCTTGAGGAGTCGGCCGGAA-3′), AP-1 sense and antisense consensus oligonucleotides were purchased from Oligos Etc (Wilsonville, OR). Biotinylated wild-type sense oligonucleotides for the NFκB and AP-1 systems contain a 5′-biotin moiety on the respective sequences shown above.
DNA immobilization and plate preparation
Biotinylated wild-type sense oligonucleotides were incubated with an equimolar amount of antisense oligonucleotides in TE, pH 7.5 (100 mM Tris/1 mM EDTA) in a 95°C heat block for 10 min. Hybridization was accomplished by removing the heat block containing the tubes from the heating element and allowing it to cool to room temperature on the benchtop for approximately 2 h. The resulting biotinylated wild-type duplexes were diluted in TE, pH 7.5 to a concentration of 0.018 nM, and 1.8 pmol was added to each well of a white 96-well streptavidin coated plate. 20, 21 Coated plates were incubated at room temperature for 1 h, tapped out, and washed 3 times with TE, pH 7.5. The washed plates were tapped out and stored in foil bags with desiccant at room temperature. These plates are functional for 1 year when stored at room temperature and are now commercially available (Pierce Biotechnology).
Extract preparation
Cells (refer to specific figure for cell type and stimulation conditions) were harvested by scraping into cold phosphate buffered saline (PBS), pH 7.2. Whole cell extracts were prepared using M-PER ® Mammalian Protein Extraction Reagents (Pierce Biotechnology), and nuclear cell fractions were prepared using NE-PER ® Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology) per the manufacturer's instructions. Aliquots were frozen and stored at -70°C. All extracts were prepared using a Halt™ protease inhibitor cocktail (Pierce Biotechnology) per the manufacturer's instructions, and sodium orthovanadate was included for all Chemiluminescent Transcription Factor Assay nuclear extractions (final concentration = 0.1 mM). Protein concentrations of cellular extracts were determined using the bicinchoninic acid method (Pierce Biotechnology).
Transcription factor DNA-binding assay (refer to Figure 1 
schematic)
Various amounts (refer to specific figure) of either whole cell or nuclear fractions were incubated with 50 µl of binding buffer in plates containing the immobilized DNA consensus sequences for 1 h at room temperature with mild agitation. For specific competitor reactions, an approximate 200-fold molar excess of either wildtype or mutant DNA duplex was added prior to adding the extract. Wells were washed 3 times with 200 µl of 1X wash solution, and 100 µl of a 1:1000 dilution of the specific primary antibody in antibody dilution buffer was added to each well and incubated for 1 h at room temperature. Wells were washed 3 times as above and 100 µl of a 1:5000 (AP-1) or 1:10,000 (NFκB) dilution of the HRPconjugated antibody in antibody dilution buffer was added to each well and incubated for 1 h at room temperature. Wells were washed 4 times as above, and 100 µl of working chemiluminescent substrate was added to each well. The chemiluminescent signal (relative light units; RLU) was detected using a TECAN SpectraFluor™ luminometer (TECAN, Männedorf, Germany). Error bars represent 1 standard deviation based on data from 3 independent sample wells (N = 3). Coefficient of Variation (CV) values measured ≤ 10%.
Electrophoretic mobility shift assay (EMSA)
EMSA results were generated using LightShift ® Chemiluminescent EMSA Kits (Pierce Biotechnology). DNAbinding reactions were performed in 1X binding buffer with various amounts of nuclear extract (refer to specific figure) . After a 20min incubation at room temperature, the reactions were loaded onto a pre-electrophoresed 6% native polyacrylamide gel in 0.5X TBE (Invitrogen/Novex, CA) and run at 100 volts for approximately 50 min. The gel was transferred to Biodyne® B positively charged nylon membrane (Pierce Biotechnology) at 10°C in 0.5X TBE for 30 min at 380 mA. The DNA duplex was crosslinked to the membrane at 120 mJ/cm 2 using a wavelength of 254 nm. Detection was accomplished per the manufacturer's instructions.
RESULTS AND DISCUSSION
The chemiluminescent plate assay was optimized with respect to duplex binding conditions and transcription factor binding parameters to achieve maximal sensitivity and dynamic range when monitoring activated populations of NFκB and AP-1 transcription factors. The amount of DNA duplex added per well of the streptavidin plates was varied and monitored by both a picogreen dye binding assay (Molecular Probes, OR) and a functional tran-scription factor binding assay developed in this study (data not shown). The functional assay yielded no significant difference in protein binding efficiency across the various amounts of DNA duplex added per well. The nature of the duplex with respect to length and distance of the consensus binding sequence from the streptavidin plate surface was also investigated. Positioning random nucleotide sequence (27 or 47 bp) or multiple synthetic C18 spacers (Glen Research, VA) between the 5′ biotin and the transcription factor binding sequence showed no significant difference in protein binding efficiency in the functional assay using either nuclear extracts or whole cell lysates (data not shown). Other key parameters optimized during development included the binding buffer used in the transcription factor capture reaction, the antibody concentration, incubation times, and wash stringencies. The resulting optimized assay was characterized with respect to sensitivity and utility as described below.
Assay characterization using nuclear and whole cell extracts
To examine the limit of detection and linearity of this assay, dose-response experiments were conducted in which decreasing amounts of both whole cell extracts and nuclear fractions were used and c-Fos activation was measured ( Figs. 2a and b ). An approximate limit of detection was defined as a stimulated signal ≥~3 times that of the equivalent unstimulated extract signal.
Whole cell extracts yielded a limit of detection of approximately 0.12 µg of extract ( Fig. 2a ). The linear range extends over 2 orders of magnitude (from 0.12 to 10 µg) with an R 2 value of 1.00. Nuclear fractions yielded a limit of detection of approximately 0.05 µg of extract (Fig. 2b) . The linear range extends over 2 orders of magnitude (from 0.05 to 6.9 µg) with an R 2 value of 0.98. Both limits of detection correspond to 300 to 500 cells from the original cultures. Similar results were achieved when c-Jun, NFκB p50, and NFκB p65 were measured (data not shown).
Free nonbiotinylated wild-type competitor duplex and mutant competitor duplex were added to the reaction in molar excess prior to addition of the stimulated extract. This ensured that the signal measured was specific for the transcription factor being monitored, and not to other nonspecific DNA-binding proteins or to the desired transcription factors adsorbing nonspecifically to the well. Extracts made from rat C6 cells were added to binding reactions containing increasing amounts of competitor duplex, and NFκB p65 activation was measured. The signal generated is specific to NFκB:DNA interactions (Fig. 3) . When 40 pmoles of the wildtype duplex was added to the reaction before the stimulated extract, 92% of the signal was eliminated. In contrast, when the same concentration of mutant duplex was added to the reaction before the same stimulated extract, no significant effect on transcription factor binding was observed. Similar results were achieved for NFκB p50, c-Fos, and c-Jun (data not shown). Since only free wild-type duplexes successfully compete away the signal, the signal gener- ated is due to the specific recognition and binding of the activated factor to its immobilized DNA consensus sequence.
Advantages of plate-based assay results versus EMSA
The electrophoretic mobility shift assay (EMSA), also known as the gel shift assay, is the traditional method for detecting DNAbinding of transcription factors. Although gel shift assays provide visible evidence of protein(s) binding to a specific DNA regulatory sequence, they may require radioisotopes and are not well suited for high-throughput applications. In addition, EMSAs cannot positively identify all possible proteins bound to the target probe. Our plate-based assay is chemiluminescent, easily amenable to highthroughput applications, and specifically identifies the protein of interest by immunodetection, thus providing a clearer image of activation or screening results.
To compare both methods, increasing amounts of HeLa cell nuclear extract from PMA/ionomycin stimulated and unstimulated cells were detected in parallel using our plate-based method and a gel shift assay technique (Fig. 4 ). Both assays show a similar degree of stimulation when comparing untreated and stimulated cells, validating that the signal seen in the plate assay format accurately reflects the characteristic increase in shifted band intensity seen using the gel shift assay. When directly compared, this highthroughput alternative yields superior sensitivity and screening potential compared to the gel shift assay.
Advantages of chemiluminescent versus colorimetric plate-based assays
Recently, more high-throughput methods have been introduced to detect and screen transcription factors. [20] [21] [22] [23] This increase in sample screening ability is directly due to adapting the gel-based EMSA system to a 96-well plate format. These plate systems provide similar high-throughput and screening capabilities to our chemiluminescent assay but offer limited sensitivity due to traditional colorimetric detection chemistry.
Our high-throughput transcription factor assay reagents are optimized for DNA binding and chemiluminescent detection, affording both a larger dynamic range and better signal-to-noise ratios when compared to colorimetric results (Fig. 5) . We defined the limit of detection (LOD) as the amount of total protein that generates a stimulated extract signal at least 3 times that of the unstimulated signal. Using this criterion, the LOD for the chemiluminescent detection system (Fig. 5a ) was 0.05 µg total nuclear protein, or approximately 20-fold more sensitive than the LOD obtained with the colorimetric kit (Fig. 5b ). Greater sensitivity with chemiluminescence translates into using less sample per well, conserving valuable sample while still obtaining reliable results.
Cellular induction of transcription factors
To further validate the transcription factor assays, we examined the effects of different substances on NIH3T3 mouse fibroblast 
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cells. Various cytokines and other molecules known to induce either NFκB, AP-1, or both were added to the cell culture media. Nuclear extracts were prepared and screened for the presence of activated NFκB p65 or c-Fos.
Tumor necrosis factor-α (TNF-α), a proinflammatory cytokine, 24 is known to induce NFκB in vivo, 25, 26 whereas phorbol 12-myristate 13-acetate (PMA), a phorbol ester, and ionomycin, a divalent calcium ionophore, 27 are known to induce the AP-1 sys- tem. As expected, the levels of NFκB p65 are greatly elevated in cells stimulated with TNF-α when compared to unstimulated cells (Fig. 6a ). In the same manner, a marked elevation of c-Fos is seen in cells stimulated with PMA/ionomycin when compared to unstimulated cells (Fig. 6b) .
The cytokine IL-1β has also been shown to stimulate NFκB in living cells. 26 Although a smaller increase is seen with IL-1β when compared to TNF-α, the increase is measurable above that of unstimulated cells (Fig. 6a) . When mouse fibroblast cells were treated with IL-2, an increase in c-Fos levels was observed (Fig.  6b ), analogous to results obtained with peripheral blood lymphocytes. 28 When these same samples were probed for activated NFκB p65, however, no stimulation was observed. This trend is similar to that seen in human polymorphonuclear neutrophils. 28 Results congruent with those in the literature are also observed when cells are treated with IL-15 28 and granulocyte macrophage colony stimulating factor (GM-CSF). 29 Lipopolysaccharide (LPS) is a major component of the cell wall of gram negative bacteria and triggers innate immune effector functions, such as the production of proinflammatory cytokines. 30 LPS would therefore be expected to induce NFκB p65, 26, 28 as well as c-Fos. Induction of both factors was observed in NIH3T3 cells in response to LPS as anticipated ( Figs. 6a and b) .
Cellular inhibition of transcription factors
Antioxidants are known to inhibit NFκB activation in cells. 31 Curcumin, a yellow coloring agent from tumeric, 32 is an antiinflammatory and chain-breaking antioxidant agent 33, 34 that is known to inhibit the activation process in vivo. Curcumin also directly inhibits DNA binding by NFκB in vitro. 34 Another chemical compound, pyrrolidine dithiocarbamate (PDTC) has been shown to inhibit the dissociation of the NFκB subunits p65 (rel A) and p50 from the inhibitory IκB subunit, thereby inhibiting the NFκB subunits's translocation to the nucleus, and subsequent downstream transcription. 35 To demonstrate the ability of our assay to measure the inhibitory effects of these 2 molecules, a dose-response experiment was performed. HeLa cells were treated with various amounts of curcumin or PDTC for 1 h at 37°C, prior to stimulation with TNFα. Nuclear extracts were prepared and probed for the presence of activated NFκB p65. A clear relationship between increasing curcumin and PDTC concentrations and NFκB p65 inhibition was observed (Fig. 7) . The cellular IC 50 , the concentration of a substance necessary to inhibit 50% of the signal, was examined to ensure our findings were within the range of those found in the literature. The IC 50 for curcumin measured at 100 µM, whereas the IC 50 for PDTC measured higher (500 µM). These values are consistent with the range reported in the literature. 31, 34 
In vitro inhibition of transcription factors
Nordihydroguaiaritic acid (NDGA) is another chain-breaking antioxidant that is similar to curcumin. 34 In addition to inhibiting NFκB activation in vivo like curcumin, NDGA also directly inhibits DNA binding by NFκB 34 and AP-1 36, 37 in vitro. A doseresponse experiment to investigate AP-1 inhibition in vitro was performed using PMA/ionomycin-induced extracts and NDGA in the wells. Nuclear extracts were incubated at room temperature for 15 min in the presence of various concentrations of NDGA. After the incubation, binding buffers, and poly dI• dC were added to the recommended concentrations, the reactions were transferred to the assay plate and the DNA binding activity of c-Fos and c-Jun was monitored. A clear relationship between increasing NDGA concentrations and c-Fos and c-Jun inhibition was demonstrated (Fig.  8a) . The in vitro IC 50 of NDGA for c-Fos and c-Jun measured 50 µM, consistent with the range reported in the literature. 36 Another compound that exerts its inhibitory effects directly on the DNA-binding activity of a transcription factor is kamebakaurin, a compound isolated from medicinal plants used in the treatment of inflammation and cancer. Kamebakaurin directly extinguishes the activation of NFκB p50 by targeting its DNAbinding activity, thereby blocking the expression of NFκB target genes. 5 The effectiveness of kamebakaurin in inhibiting binding of NFκB p50 to DNA was determined using the chemiluminescent plate-based transcription factor assay (Fig. 8b) . The observed in vitro IC 50 of kamebakaurin for NFκB p50 of 10 µM is within the range of values documented in the literature. 5
CONCLUSIONS
In this study, we have developed and evaluated a chemiluminescent DNA-based ELISA assay that can be used to assess the DNA-binding activity of transcription factors. This assay is simple, robust, reproducible, and adaptable to automation, FIG. 7 . In vivo inhibition of NFkB p65 in HeLa cells using curcumin and PDTC. Different concentrations of curcumin and PDTC were incubated with HeLa cells for 1 h. Following this treatment, TNF-α was added directly to the cell culture media at a concentration of 25 ng/ml, and the cells were incubated under the same conditions for 20 min. Nuclear extracts were prepared, and 3 mg of each extract was assayed using reagents specific to NFkB p65. Error bars represent 1 standard deviation based on data from 3 independent sample wells (N = 3). 
